Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Beat The Street With SI Traders -- Ignore unavailable to you. Want to Upgrade?

To: E. Charters who wrote (91750)	12/19/2011 10:53:39 AM
From: Postman	Read Replies (3) \| Respond to of 233883

GNBT developing a breast vaccine- they should be getting some good exposure on Bloomberg TV today at 3 pm-share price is rising.............this is a Canadian company ------------------------- Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today Segment Scheduled to Air at 6 pm EST WORCESTER, Mass. and TORONTO, Dec. 19, 2011 /PRNewswire via COMTEX/ -- Generex Biotechnology Corporation (OTCBB:GNBT.OB) today announced that Bloomberg Television is scheduled to air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. The segment is scheduled to air at 6 pm EST (3 pm PST) today, Monday, December 19, 2011 (see promo at http://i879.photobucket.com/albums/ab357/tc2000chartreader/72389a92.mp4. It is expected that, once aired, the segment will be available for viewing on the Bloomberg website and on the Generex website. (Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b ) The story will cover the Company's novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37), which is the subject of an ongoing Phase 2 clinical study in patients with HER-2 expressing breast cancer. The segment will be featured in Bloomberg's "Innovators" segment, which focuses on world-changing technologies and innovations. The segment will include an interview by Bloomberg reporter Cali Carlin of Dr. Eric von Hofe, Ph.D., President of Antigen Express, and COL George E. Peoples, MD, FACS, Director, Cancer Vaccine Development Program. Antigen Express has pioneered technology for increasing the potency of therapeutic anti-cancer vaccines. Initial clinical studies showed that its lead compound, AE37, indeed showed surprisingly potent immunological activity without sacrificing any specificity in the immune response. For the last four years, AE37 has been in a controlled, randomized Phase II study to determine whether it can indeed prevent recurrences in patients who have had breast cancer. Positive interim results from that study were recently presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). Final Phase 2 results are expected in 2012. The Antigen Express AE37 breast cancer vaccine was also featured in Newsweek magazine on December 12, 2011 in science columnist and science editor Sharon Begley's article, Could This Be The End of Cancer?:( http://www.thedailybeast.com/newsweek/2011/12/11/could-this-be-the-end-of-cancer.html)." About Generex Biotechnology Corporation